
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BACE CRISPR/Cas9 KO Plasmid (h2) | sc-401500-KO-2 | 20 µg | $397.00 |
BACE1 encodes beta-site amyloid precursor protein cleaving enzyme 1 (BACE), an aspartyl protease that initiates the amyloidogenic processing of APP by generating the N-terminus of Aβ peptides. This activity intersects with endosomal trafficking and lysosomal proteostasis, where acidic compartments support BACE maturation and substrate cleavage. BACE1-dependent processing influences synaptic function and neuronal signaling by modulating levels of APP-derived fragments and other neuronal substrates. Dysregulated BACE1 expression or activity has been associated with Alzheimer’s disease-related molecular pathology and is frequently studied in the context of amyloid pathway biology and neurodegeneration mechanisms.
BACE CRISPR/Cas9 KO Plasmid (h2) is a pool of plasmids designed for targeted disruption of the BACE1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the BACE1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the BACE1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish BACE protein expression.
This CRISPR knockout system enables efficient generation of BACE1-deficient cell models for investigation of BACE signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.